The infusion from the two pharmaceutical giants brings PathAI’s total Series B funding to $75 million; the startup initially raised $60 million in the round in April. Since its 2016 founding, the Boston-based PathAI has now raised more than $90 million.
The funding will support PathAI’s growing capabilities in clinical development. As David Rubin, PhD, managing director of the Merck innovation fund, explained in a news release, “[PathAI’s] industry-leading work incorporating artificial intelligence into digital pathology holds the potential to change the way we diagnose and treat cancer.”
More articles on AI:
Geisinger, Mayo Clinic, IBM among 25 participants chosen for CMS AI challenge
Patients don’t trust AI — here’s how providers can change that
How Facebook, NYU School of Medicine are using AI to speed MRI readings
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
